<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="294ca864-10cd-474e-abd1-9f5112249853"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use XERAVA safely and effectively. See full prescribing information for XERAVA. <br/>
      <br/>
      <content styleCode="bold">XERAVA<sup>®</sup> (eravacycline) for injection, for intravenous use</content>
      <br/>Initial U.S. Approval: 2018</title>
   <effectiveTime value="20250403"/>
   <setId root="a4b188d4-f467-470c-ad7b-25ffbdd8862a"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="790935717"/>
            <name>Tetraphase Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="480604772"/>
                        <name>SGS Société Générale de Surveillance SA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="ANALYSIS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71773-050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="ANALYSIS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71773-100" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="d8ed86ce-81d0-454e-b63c-089e9fb60cf5"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250331"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71773-050" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Xerava</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>eravacycline</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WK1NMH89VJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ERAVACYCLINE DIHYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="07896928ZC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ERAVACYCLINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71773-050-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180910"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="12" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71773-050-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180910"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA211109" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180910"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71773-100" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Xerava</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>eravacycline</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WK1NMH89VJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ERAVACYCLINE DIHYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="07896928ZC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ERAVACYCLINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71773-100-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="12" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="71773-100-12" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20200914"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA211109" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180910"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="45bedc4e-dcdb-44e2-8e66-a3a360ba0a0f"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="right" valign="bottom"/>
                           <tbody>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#ID_e291adc8-5e0d-440a-b8e8-d142231c677e">2.4</linkHtml>)</td>
                                 <td>12/2024</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions, Tetracycline Class Adverse Reactions (<linkHtml href="#ID_eccd5b86-837b-4e59-897f-15ff76a9087f">5.5</linkHtml>)</td>
                                 <td>3/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_12c989bd-6991-4078-badc-41db09126a49">
               <id root="64d36fff-6c4c-4fb4-adfb-9c5643993ef7"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra‑abdominal infections in patients 18 years of age and older. (<linkHtml href="#ID_c2a056f3-64cd-4f0b-965a-806a797babf3">1.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use <br/>
                           </content>XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI). (<linkHtml href="#ID_c2a056f3-64cd-4f0b-965a-806a797babf3">1.1</linkHtml>)</paragraph>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (<linkHtml href="#ID_13482e6c-437a-4b9f-b49d-ced8b5f3afb1">1.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_c2a056f3-64cd-4f0b-965a-806a797babf3">
                     <id root="a62abcd1-aee8-40cf-8de9-e1765b7cd038"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Complicated Intra-abdominal Infections </title>
                     <text>
                        <paragraph>XERAVA is indicated for the treatment of complicated intra‑abdominal infections (cIAI) caused by susceptible microorganisms: <content styleCode="italics">Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus</content> group, <content styleCode="italics">Clostridium perfringens</content>, <content styleCode="italics">Bacteroides</content> species, and <content styleCode="italics">Parabacteroides distasonis</content> in patients 18 years or older <content styleCode="italics">[see Microbiology (<linkHtml href="#ID_3bbe2352-ce01-4e81-a4c7-2a1483538e63">12.4</linkHtml>) and Clinical Studies (<linkHtml href="#ID_be43b4ac-847d-48e6-8654-73cde4f6d12e">14.1</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_04ce8778-fbe2-42d7-a27b-d761c55cbad6">14.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_13482e6c-437a-4b9f-b49d-ced8b5f3afb1">
                     <id root="d6d5c03e-c140-416e-9c54-31f9badfd983"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Usage </title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3bc913d8-85c2-48cb-98fa-eab1d8a5afe6">
               <id root="340d0aa2-b111-4b46-ae20-957cb27e09c7"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Administer XERAVA for injection 1 mg/kg by intravenous infusion over approximately 60 minutes every 12 hours for a total duration of 4 to 14 days. (<linkHtml href="#ID_0ac53d85-68d1-4764-b5aa-6ad0418df5d1">2.1</linkHtml>)</item>
                           <item>Severe Hepatic Impairment (Child Pugh C): 1 mg/kg XERAVA every 12 hours on Day 1, then 1 mg/kg every 24 hours starting on Day 2 for a total duration of 4 to 14 days. (<linkHtml href="#ID_cacc3d19-8be5-4c5b-910c-ff8dcdc57a4c">2.2</linkHtml>)</item>
                           <item>Concomitant Use of a Strong Cytochrome P450 (CYP) Isoenzyme 3A Inducer: 1.5 mg/kg XERAVA every 12 hours for a total duration of 4 to 14 days. (<linkHtml href="#ID_1a770201-a6a0-4734-a79a-d62d44e98eec">2.3</linkHtml>)</item>
                           <item>See full prescribing information for the preparation of XERAVA. (<linkHtml href="#ID_e291adc8-5e0d-440a-b8e8-d142231c677e">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_0ac53d85-68d1-4764-b5aa-6ad0418df5d1">
                     <id root="dbfeb2b8-abbc-4c2d-8ad0-73df4637d4d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Adult Dosage </title>
                     <text>
                        <paragraph>The recommended dose regimen of XERAVA is 1 mg/kg every 12 hours.  Administer intravenous infusions of XERAVA over approximately 60 minutes every 12 hours.</paragraph>
                        <paragraph>The recommended duration of treatment with XERAVA for cIAI is 4 to 14 days.  The duration of therapy should be guided by the severity and location of infection and the patient's clinical response.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_cacc3d19-8be5-4c5b-910c-ff8dcdc57a4c">
                     <id root="f2281eb1-e7fd-4035-9bd0-022fab76bb90"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage Modifications in Patients with Hepatic Impairment </title>
                     <text>
                        <paragraph>In patients with severe hepatic impairment (Child Pugh C), administer XERAVA 1 mg/kg every 12 hours on Day 1 followed by XERAVA 1 mg/kg every 24 hours starting on Day 2 for a total duration of 4 to 14 days. No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B) <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_ddbc923f-d040-4fde-bdbe-dcbb70a4d3dd">8.6</linkHtml>) and Clinical Pharmacology (<linkHtml href="#ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1a770201-a6a0-4734-a79a-d62d44e98eec">
                     <id root="315042a9-c3db-48fd-ae8e-d77d4994c2b1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Modifications in Patients with Concomitant Use of a Strong Cytochrome P450 (CYP) Isoenzyme 3A Inducer </title>
                     <text>
                        <paragraph>With concomitant use of a strong CYP3A inducer, administer XERAVA 1.5 mg/kg every 12 hours for a total duration of 4 to 14 days. No dosage adjustment is warranted in patients with concomitant use of a weak or moderate CYP3A inducer <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_1f272349-df5d-4cbb-90bc-4ac8fbaa272f">7.1</linkHtml>) and Clinical Pharmacology (<linkHtml href="#ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e291adc8-5e0d-440a-b8e8-d142231c677e">
                     <id root="95f2fafd-bbb3-4dea-b69e-b3dc583af3f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Preparation and Administration</title>
                     <text>
                        <paragraph>XERAVA is for intravenous infusion only. Each vial is for a single dose only.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Preparation</content>
                        </paragraph>
                        <paragraph>XERAVA is supplied as a sterile yellow to orange dry powder in a single-dose vial that must be reconstituted and further diluted prior to intravenous infusion as outlined below. XERAVA does not contain preservatives. Aseptic technique must be used for reconstitution and dilution as follows:</paragraph>
                        <paragraph/>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Calculate the dose of XERAVA based on the patient weight (1 mg/kg actual body weight).  Prepare the required dose for intravenous infusion by reconstituting the appropriate number of vials needed.  Reconstitute each vial of XERAVA with 5 mL of Sterile Water for Injection, USP or with 5 mL of 0.9% Sodium Chloride Injection, USP, which will deliver the following: 	<list listType="unordered" styleCode="disc">
                                 <item>XERAVA 50 mg vial will deliver 50 mg (10 mg/mL) of eravacycline (free base equivalents).</item>
                                 <item>XERAVA 100 mg vial will deliver 100 mg (20 mg/mL) of eravacycline (free base equivalents).</item>
                              </list>
                           </item>
                           <item>Swirl the vial gently until the powder has dissolved entirely.  Avoid shaking or rapid movement as it may cause foaming.  The reconstituted XERAVA solution should be a clear, pale yellow to orange solution.  Do not use the solution if you notice any particles or the solution is cloudy.  Reconstituted solution is not for direct injection. The stability of the solution after reconstitution in the vial has been demonstrated for 1 hour at room temperature (not to exceed 25°C/77°F). If the reconstituted solution in the vial is not diluted in the infusion bag within 1 hour, the reconstituted vial content must be discarded.</item>
                           <item>The reconstituted XERAVA solution is further diluted for intravenous infusion to a target concentration of 0.3 mg/mL, in a 0.9% Sodium Chloride Injection, USP infusion bag before intravenous infusion. To dilute the reconstituted solution, withdraw the full or partial reconstituted vial content from each vial and add it into the infusion bag to generate an infusion solution with a target concentration of 0.3 mg/mL (within a range of 0.2 to 0.6 mg/mL). Do not shake the bag.</item>
                           <item>
                              <content styleCode="xmChange">The diluted solutions must be infused within 12 hours if stored at room temperature (not to exceed 25°C/77°F) or within 8 days if stored refrigerated at 2°C to 8°C (36°F to 46°F).  Reconstituted XERAVA solutions and diluted XERAVA infusion solutions should not be frozen.</content>
                           </item>
                           <item>Visually inspect the diluted XERAVA solution for particulate matter and discoloration prior to administration (the XERAVA infusion solution for administration is clear and ranges from light yellow to orange). Discard unused portions of the reconstituted and diluted solution.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Administration of the Intravenous Infusion</content>
                        </paragraph>
                        <paragraph>The diluted XERAVA solution is administered as an intravenous infusion over approximately 60 minutes.</paragraph>
                        <paragraph>XERAVA may be administered intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of XERAVA with 0.9% Sodium Chloride Injection, USP.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_60475d06-7c27-44d2-bfd6-e70c812bffca">
                     <id root="82619184-0fd3-41bf-8978-44a5fcdabb7b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Drug Compatibilities </title>
                     <text>
                        <paragraph>XERAVA is compatible with 0.9% Sodium Chloride Injection, USP. The compatibility of XERAVA with other drugs and infusion solutions has not been established.  XERAVA should not be mixed with other drugs or added to solutions containing other drugs.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f89f9aac-e3e4-4dbc-bbdb-afa3ba60d326">
               <id root="bbd36761-1ea3-4bc2-a41f-73e340045bf1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>XERAVA for injection is a yellow to orange, sterile, preservative-free, lyophilized powder in single-dose vials for reconstitution and further dilution. XERAVA is available in two strengths:</paragraph>
                  <list listType="unordered">
                     <item>50 mg of eravacycline (equivalent to 63.5 mg eravacycline dihydrochloride)</item>
                     <item>100 mg of eravacycline (equivalent to 127 mg eravacycline dihydrochloride)</item>
                  </list>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">For injection</content>: 50 mg and 100 mg of eravacycline (equivalent to 63.5 mg and 127 mg eravacycline dihydrochloride, respectively) as a lyophilized powder in a single-dose vial for reconstitution and further dilution. (<linkHtml href="#ID_f89f9aac-e3e4-4dbc-bbdb-afa3ba60d326">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_0d591bf0-e942-484b-9d34-fa2c669b8f2d">
               <id root="896c44d3-3ca9-49d3-92b2-4d368bac0a9c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs, or to any of the excipients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_9e37a7d7-ea50-46ca-934c-1605bf33c856">5.1</linkHtml>) and Adverse Reactions (<linkHtml href="#ID_26671520-ac5d-4b6d-8db8-37d8b6721abd">6.1</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs, or any of the excipients in XERAVA. (<linkHtml href="#ID_0d591bf0-e942-484b-9d34-fa2c669b8f2d">4</linkHtml>, <linkHtml href="#ID_34da32e2-e9f6-44df-b054-a4109cabfb9c">5</linkHtml>, <linkHtml href="#ID_de903add-be28-4d1c-9e6a-cd64408a4ee4">6</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_34da32e2-e9f6-44df-b054-a4109cabfb9c">
               <id root="414d1c0a-36f2-4ae5-b939-0b4c56c58654"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Hypersensitivity Reactions</content>: Life-threatening hypersensitivity (anaphylactic) reactions have been reported with tetracycline antibacterial drugs, including XERAVA. Avoid use in patients with known hypersensitivity to tetracyclines. (<linkHtml href="#ID_9e37a7d7-ea50-46ca-934c-1605bf33c856">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Tooth Discoloration and Enamel Hypoplasia</content>: The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. (<linkHtml href="#ID_a0412d53-1485-4084-9e90-8b7919a79779">5.2</linkHtml>, <linkHtml href="#ID_eaa6d5fd-17eb-4fcb-9811-853d5ab7f44f">8.1</linkHtml>, <linkHtml href="#ID_ee4ac1ba-ab86-44cf-a8f1-bbb402e0dfee">8.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Inhibition of Bone Growth</content>: The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. (<linkHtml href="#ID_b8b6bbaa-7734-4531-b453-59aee592b3f4">5.3</linkHtml>, <linkHtml href="#ID_eaa6d5fd-17eb-4fcb-9811-853d5ab7f44f">8.1</linkHtml>, <linkHtml href="#ID_ee4ac1ba-ab86-44cf-a8f1-bbb402e0dfee">8.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">
                                 <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea:</content> Evaluate if diarrhea occurs. (<linkHtml href="#ID_2fb939d7-7b08-4c58-926c-0b274feebc69">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_9e37a7d7-ea50-46ca-934c-1605bf33c856">
                     <id root="2924b8f4-5973-494b-988a-30918024302c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_26671520-ac5d-4b6d-8db8-37d8b6721abd">6.1</linkHtml>)]</content>.  XERAVA is structurally similar to other tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline- class antibacterial drugs. Discontinue XERAVA if an allergic reaction occurs.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a0412d53-1485-4084-9e90-8b7919a79779">
                     <id root="151c143b-40b0-4e79-aecc-e212e9aca38a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Tooth Discoloration and Enamel Hypoplasia </title>
                     <text>
                        <paragraph>The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-grey-brown). This adverse reaction is more common during long-term use of the tetracycline class drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported with tetracycline class drugs. Advise the patient of the potential risk to the fetus if XERAVA is used during the second or third trimester of pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_eaa6d5fd-17eb-4fcb-9811-853d5ab7f44f">8.1</linkHtml>, <linkHtml href="#ID_ee4ac1ba-ab86-44cf-a8f1-bbb402e0dfee">8.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b8b6bbaa-7734-4531-b453-59aee592b3f4">
                     <id root="847dcbcd-139c-471a-9641-eb5f318f84e9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Inhibition of Bone Growth </title>
                     <text>
                        <paragraph>The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.  All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued. Advise the patient of the potential risk to the fetus if XERAVA is used during the second or third trimester of pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_eaa6d5fd-17eb-4fcb-9811-853d5ab7f44f">8.1</linkHtml>, <linkHtml href="#ID_ee4ac1ba-ab86-44cf-a8f1-bbb402e0dfee">8.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2fb939d7-7b08-4c58-926c-0b274feebc69">
                     <id root="e9e68edc-cb72-406e-88b3-cfad02c7da98"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. </paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_eccd5b86-837b-4e59-897f-15ff76a9087f">
                     <id root="60bbcaba-f4e5-4611-a9fd-e2b0846faf10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Tetracycline Class Adverse Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, fixed drug eruption,  pseudotumor cerebri, and anti‑ anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions is suspected.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2d7ede7e-3125-4540-8f1c-bb8af583f988">
                     <id root="d7f21303-567f-406c-80de-ddd7fd4376d5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Potential for Microbial Overgrowth </title>
                     <text>
                        <paragraph>XERAVA use may result in overgrowth of non-susceptible organisms, including fungi. If such infections occur, discontinue XERAVA and institute appropriate therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6b121c01-fe46-4c7b-ba9b-200aa7a04338">
                     <id root="020c96fc-280b-45a1-b69e-1f2b12eb288e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Development of Drug-Resistant Bacteria </title>
                     <text>
                        <paragraph>Prescribing XERAVA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria <content styleCode="italics">[see Indications and Usage (<linkHtml href="#ID_13482e6c-437a-4b9f-b49d-ced8b5f3afb1">1.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_de903add-be28-4d1c-9e6a-cd64408a4ee4">
               <id root="61653ee9-55f5-4ed0-97fe-7a552e288ecc"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described in greater detail in the Warnings and Precautions section:</paragraph>
                  <list listType="unordered">
                     <item>Hypersensitivity Reactions <content styleCode="italics">[Warning and Precautions (<linkHtml href="#ID_9e37a7d7-ea50-46ca-934c-1605bf33c856">5.1</linkHtml>)]</content>
                     </item>
                     <item>Tooth Discoloration [<content styleCode="italics">Warning and Precautions (<linkHtml href="#ID_a0412d53-1485-4084-9e90-8b7919a79779">5.2</linkHtml>)]</content>
                     </item>
                     <item>Inhibition of Bone Growth<content styleCode="italics"> [Warning and Precautions (<linkHtml href="#ID_b8b6bbaa-7734-4531-b453-59aee592b3f4">5.3</linkHtml>)]</content>
                     </item>
                     <item>
                        <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea<content styleCode="italics"> [Warning and Precautions (<linkHtml href="#ID_2fb939d7-7b08-4c58-926c-0b274feebc69">5.4</linkHtml>)]</content>
                     </item>
                     <item>Tetracycline Class Adverse Reactions <content styleCode="italics">[Warning and Precautions (<linkHtml href="#ID_eccd5b86-837b-4e59-897f-15ff76a9087f">5.5</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence ≥ 3%) are infusion site reactions, nausea, and vomiting. (<linkHtml href="#ID_26671520-ac5d-4b6d-8db8-37d8b6721abd">6.1</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Tetraphase Pharmaceuticals, Inc., at 1-800-651-3861</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_26671520-ac5d-4b6d-8db8-37d8b6721abd">
                     <id root="f74518e4-1c55-47d5-b08a-640d308e3ff2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>XERAVA was evaluated in 3 active-controlled clinical trials (Trial 1, Trial 2, and Trial 3) in adults with cIAI. These trials included two Phase 3 trials (Trial 1 and Trial 2) and one Phase 2 trial (Trial 3, NCT01265784). The Phase 3 trials included 520 patients treated with XERAVA and 517 patients treated with comparator antibacterial drugs (ertapenem or meropenem). The median age of patients treated with XERAVA was 56 years, ranging between 18 and 93 years old; 30% were age 65 years and older. Patients treated with XERAVA were predominantly male (57%) and Caucasian (98%). The XERAVA-treated population included 31% obese patients (BMI ≥ 30 kg/m2) and 8% with baseline moderate to severe renal impairment (calculated creatinine clearance 15 to less than 60 mL/min). Among the trials, 66 (13%) of patients had baseline moderate hepatic impairment (Child Pugh B); patients with severe hepatic impairment (Child Pugh C) were excluded from the trials.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Leading to Discontinuation</content>
                        </paragraph>
                        <paragraph>Treatment discontinuation due to an adverse reaction occurred in 2% (11/520) of patients receiving XERAVA and 2% (11/517) of patients receiving the comparator. The most commonly reported adverse reactions leading to discontinuation of XERAVA were related to gastrointestinal disorders.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Most Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Adverse reactions occurring at 3% or greater in patients receiving XERAVA were infusion site reactions, nausea, and vomiting.</paragraph>
                        <paragraph>Table 1 lists adverse reactions occurring in ≥ 1% of patients receiving XERAVA and with incidences greater than the comparator in the Phase 3 cIAI clinical trials. A similar adverse reaction profile was observed in the Phase 2 cIAI clinical trial (Trial 3).</paragraph>
                        <table cellpadding="3.6pt" width="75%">
                           <caption>Table 1: Selected Adverse Reactions Reported in ≥ 1% of Patients Receiving XERAVA in the Phase 3 cIAI Trials (Trial 1 and Trial 2)</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th valign="bottom" styleCode="Lrule Rrule">												Adverse Reactions 											</th>
                                 <th styleCode="Rrule">												XERAVA<footnote>XERAVA dose equals 1 mg/kg every 12 hours IV.</footnote>
                                    <br/>N=520<br/>n (%) 											</th>
                                 <th styleCode="Rrule">												Comparators<footnote>Comparators include ertapenem 1 g every 24 hours IV and meropenem 1 g every 8 hours IV.</footnote>
                                    <br/>N=517<br/>n (%) 											</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">Abbreviations: IV=intravenous</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">												Infusion site reactions<footnote>Infusion site reactions include: catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoaesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, phlebitis superficial, thrombophlebitis, and vessel puncture site swelling.</footnote>
                                 </td>
                                 <td styleCode="Rrule">												40 (7.7) 											</td>
                                 <td styleCode="Rrule">												10 (1.9) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">												Nausea 											</td>
                                 <td styleCode="Rrule">												34 (6.5) 											</td>
                                 <td styleCode="Rrule">												3 (0.6) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">												Vomiting 											</td>
                                 <td styleCode="Rrule">												19 (3.7) 											</td>
                                 <td styleCode="Rrule">												13 (2.5) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">												Diarrhea 											</td>
                                 <td styleCode="Rrule">												12 (2.3) 											</td>
                                 <td styleCode="Rrule">												8 (1.5) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">												Hypotension 											</td>
                                 <td styleCode="Rrule">												7 (1.3) 											</td>
                                 <td styleCode="Rrule">												2 (0.4) 											</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">												Wound dehiscence 											</td>
                                 <td styleCode="Rrule">												7 (1.3) 											</td>
                                 <td styleCode="Rrule">												1 (0.2) 											</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Other Adverse Reactions of XERAVA</content>
                        </paragraph>
                        <paragraph>The following selected adverse reactions were reported in XERAVA-treated patients at a rate of less than 1% in the Phase 3 trials:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac disorders:</content> palpitations</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal System:</content> acute pancreatitis, pancreatic necrosis</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administrative Site Conditions:</content> chest pain</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders:</content> hypersensitivity</paragraph>
                        <paragraph>
                           <content styleCode="italics">Laboratory Investigations:</content> increased amylase, increased lipase, increased alanine aminotransferase, prolonged activated partial thromboplastin time, decreased renal clearance of creatinine, increased gamma-glutamyltransferase, decreased white blood cell count, neutropenia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and nutrition disorders:</content> hypocalcemia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System:</content> dizziness, dysgeusia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric disorders:</content> anxiety, insomnia, depression</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic, and Mediastinal System:</content> pleural effusion, dyspnea</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders:</content> rash, hyperhidrosis</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_eeaf0d4e-356f-4e49-a33a-bcf9d6a36d8c">
               <id root="f691d7d4-ac44-4e2c-ad77-a75597746d92"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Strong CYP 3A Inducers:</content> Co-administration decreases the exposure of eravacycline; increase XERAVA dose with concomitant use. (<linkHtml href="#ID_1a770201-a6a0-4734-a79a-d62d44e98eec">2.3</linkHtml>, <linkHtml href="#ID_1f272349-df5d-4cbb-90bc-4ac8fbaa272f">7.1</linkHtml>, <linkHtml href="#ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d">12.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Anticoagulant Drugs:</content> Downward adjustment of anticoagulant dosage may be required. (<linkHtml href="#ID_61a89304-f776-47e5-b5ff-43356c61b326">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_1f272349-df5d-4cbb-90bc-4ac8fbaa272f">
                     <id root="47d0229e-ba98-4c69-af53-1f901afd280b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on XERAVA </title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="20f89aae-3534-4317-a652-c0f7ca56a4da"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strong CYP3A Inducers</content>
                              </paragraph>
                              <paragraph>Concomitant use of strong CYP3A inducers decreases the exposure of eravacycline, which may reduce the efficacy of XERAVA <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d">12.3</linkHtml>)]</content>.  Increase XERAVA dose in patients with concomitant use of a strong CYP3A inducer <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_1a770201-a6a0-4734-a79a-d62d44e98eec">2.3</linkHtml>)]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_61a89304-f776-47e5-b5ff-43356c61b326">
                     <id root="ceaf7f44-9911-4163-9683-5bab048e2c2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effect of XERAVA on other Drugs</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="88e666ce-7b1d-44f0-be3b-c1e95abec68e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Anticoagulant Drugs</content>
                              </paragraph>
                              <paragraph>Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_bc5467e4-1c32-4102-8e80-3dcc0d8079dd">
               <id root="59616e91-9a41-4e4e-b58b-6a31f5e7e34b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation:</content> Breastfeeding is not recommended during treatment with XERAVA. (<linkHtml href="#ID_2d8b6b6a-fa0d-4906-bd83-18d4611d6864">8.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_eaa6d5fd-17eb-4fcb-9811-853d5ab7f44f">
                     <id root="933e716d-00ae-40aa-a875-0ad0c9f6a9e7"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section ID="ID_8964f1c0-321f-4cd4-80d4-62ff7db0149b">
                           <id root="237b393d-89c8-4dd2-b7c7-fdcff3286254"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>XERAVA, like other tetracycline-class antibacterial drugs, may cause discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimester of pregnancy<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#ID_9e37a7d7-ea50-46ca-934c-1605bf33c856">5.1</linkHtml>, <linkHtml href="#ID_a0412d53-1485-4084-9e90-8b7919a79779">5.2</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_ee4ac1ba-ab86-44cf-a8f1-bbb402e0dfee">8.4</linkHtml>)]</content>. The limited available data with XERAVA use in pregnant women are insufficient to inform drug‑associated risk of major birth defects and miscarriages.  Animal studies indicate that eravacycline crosses the placenta and is found in fetal plasma; doses greater than approximately 3- and 2.8- times the clinical exposure, based on AUC in rats and rabbits, respectively, administered during the period of organogenesis, were associated with decreased ossification, decreased fetal body weight, and/or increased post-implantation loss <content styleCode="italics">(see <linkHtml href="#ID_b1c63a34-c07c-4bb8-8340-285b63159251">Data</linkHtml>).</content>
                              </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_b1c63a34-c07c-4bb8-8340-285b63159251">
                           <id root="8b3c6c38-9ddb-4103-85ca-7eb408c0567a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>Embryo-fetal development studies in rats and rabbits reported no treatment-related effects at approximately 3 and 2.8 times the clinical exposure (based on AUC). Dosing was during the period of organogenesis, i.e., gestation days 7-17 in rats and gestation days 7-19 in rabbits. Higher doses, approximately 8.6 and 6.3 times the clinical exposure (based on AUC) in rats and rabbits, respectively, were associated with fetal effects including increased post-implantation loss, reduced fetal body weights, and delays in skeletal ossification in both species, and abortion in the rabbit.</paragraph>
                              <paragraph>A peri-natal and post-natal rat toxicity study demonstrated that eravacycline crosses the placenta and is found in fetal plasma following intravenous administration to the dams. This study did not demonstrate anatomical malformations, but there were early decreases in pup weight that were later comparable to controls and a non-significant trend toward increased stillbirths or dead pups during lactation. F1 males from dams treated with 10 mg/kg/day eravacycline that continued to fertility testing had decreased testis and epididymis weights at approximately post-natal day 111 that may have been at least partially related to lower body weights in this group.</paragraph>
                              <paragraph>Tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity also has been noted in animals treated early in pregnancy.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_2d8b6b6a-fa0d-4906-bd83-18d4611d6864">
                     <id root="b129840f-6c5c-4bc5-8611-4402c1457c93"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section ID="ID_1e6692fd-f241-4fb6-af3e-a55fc27b8811">
                           <id root="85ebdad2-231e-4e90-bcbd-3f8212434264"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>It is not known whether XERAVA is excreted in human breast milk.  Eravacycline (and its metabolites) is excreted in the milk of lactating rats (<content styleCode="italics">see <linkHtml href="#ID_3edbde20-f0e0-417f-96ae-ddf7e8c765be">Data</linkHtml>
                                 </content>). Tetracyclines are excreted in human milk; however, the extent of absorption of tetracyclines, including eravacycline, by the breastfed infant is not known.  There are no data on the effects of XERAVA on the breastfed infant, or the effects on milk production.  Because there are other antibacterial drug options available to treat cIAI in lactating women and because of the potential for serious adverse reactions, including tooth discoloration and inhibition of bone growth, advise patients that breastfeeding is not recommended during treatment with XERAVA and for 4 days (based on half-life) after the last dose.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_3edbde20-f0e0-417f-96ae-ddf7e8c765be">
                           <id root="96646bc5-19a7-408b-9dac-aa184ce1682a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>Eravacycline (and its metabolites) was excreted in the milk of lactating rats on post-natal day 15 following intravenous administration of 3, 5, and 10 mg/kg/day eravacycline.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_4267d928-355a-4dee-8ae9-9dcf4cc31320">
                     <id root="e514662c-beb1-4b3f-bb7c-0d459f295ca3"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential </title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section ID="ID_8c3a31fa-dfe1-4b01-8729-1f1c7022c2ce">
                           <id root="2c608d9d-02d2-41d8-ac2d-d344020dac9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Infertility</content>
                           </title>
                           <text>
                              <paragraph>Based on animal studies, XERAVA can lead to impaired spermiation and sperm maturation, resulting in abnormal sperm morphology and poor motility.  The effect is reversible in rats. The long-term effects of XERAVA on male fertility have not been studied <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#ID_788fe52c-2e3e-41d8-b1e4-4101843e11dd">13.1</linkHtml>)].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_ee4ac1ba-ab86-44cf-a8f1-bbb402e0dfee">
                     <id root="d117885f-cf8f-4acd-9157-e724e4430f53"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of XERAVA in pediatric patients have not been established. </paragraph>
                        <paragraph>Due to the adverse effects of the tetracycline-class of drugs, including XERAVA on tooth development and bone growth, use of XERAVA in pediatric patients less than 8 years of age is not recommended <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_9e37a7d7-ea50-46ca-934c-1605bf33c856">5.1</linkHtml>, <linkHtml href="#ID_a0412d53-1485-4084-9e90-8b7919a79779">5.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_11d93f39-3b91-4ef3-9547-8a54bf2ea93e">
                     <id root="dcc8aa25-e8f5-44cf-9517-378eae35acab"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the total number of patients with cIAI who received XERAVA in Phase 3 clinical trials (n = 520), 158 subjects were ≥ 65 years of age, while 59 subjects were ≥ 75 years of age.  No overall differences in safety or efficacy were observed between these subjects and younger subjects. </paragraph>
                        <paragraph>No clinically relevant differences in the pharmacokinetics of eravacycline were observed with respect to age in a population pharmacokinetic analysis of eravacycline <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ddbc923f-d040-4fde-bdbe-dcbb70a4d3dd">
                     <id root="d5f89b1f-3764-488b-83db-72691a6838f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment is warranted for XERAVA in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B). Adjust XERAVA dosage in patients with severe hepatic impairment (Child Pugh C) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_cacc3d19-8be5-4c5b-910c-ff8dcdc57a4c">2.2</linkHtml>) and Clinical Pharmacology (<linkHtml href="#ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9140c8ff-3b63-4110-8986-014f0fdd2042">
                     <id root="4a58ca82-4a9d-4f80-b92d-464ed60d2ee1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment is necessary for XERAVA in patients with renal impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3010a0da-d478-4798-a97a-3a356aeca8c3">
               <id root="56e396d2-dcb4-4325-bdf6-95c676c025bc"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>No reports of overdose were reported in clinical trials.  In the case of suspected overdose, XERAVA should be discontinued and the patient monitored for adverse reactions. Hemodialysis is not expected to remove significant quantities of XERAVA <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d">12.3</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="ID_df9c5c28-7f82-4f2d-862d-a77674d3bbe4">
               <id root="471566dc-780f-4c5e-8635-a2293dce1a2d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>XERAVA contains eravacycline, a synthetic tetracycline-class antibacterial agent for intravenous administration.  Chemically, eravacycline is a C7-, C9-substituted sancycline derivative. The chemical name of eravacycline dihydrochloride is [(4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[2‑(pyrrolidin-1-yl) acetamido]-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide] dihydrochloride.  The molecular formula for eravacycline dihydrochloride is C<sub>27</sub>H<sub>31</sub>FN<sub>4</sub>O<sub>8</sub>•2HCl, and its molecular weight is 631.5. </paragraph>
                  <paragraph>The following represents the chemical structure of eravacycline dihydrochloride:</paragraph>
                  <paragraph>
                     <renderMultiMedia ID="id1109011818" referencedObject="ID_86cb7053-9aa5-433d-a2cc-11b3e60e41cd"/>
                  </paragraph>
                  <paragraph>XERAVA is a sterile, preservative-free, yellow to orange, lyophilized powder in a glass single-dose vial for intravenous infusion after reconstitution and dilution. XERAVA is supplied in two (2) strengths as follows: </paragraph>
                  <list listType="unordered">
                     <item>Each 50 mg single-dose vial contains 50 mg of eravacycline (equivalent to 63.5 mg of eravacycline dihydrochloride) and the excipient, mannitol (150 mg).  Sodium hydroxide and hydrochloric acid are used as needed for pH adjustment to 5.5 to 7.0.</item>
                     <item>Each 100 mg single-dose vial contains 100 mg of eravacycline (equivalent to 127 mg of eravacycline dihydrochloride) and the excipient, mannitol (150 mg).  Sodium hydroxide and hydrochloric acid are used as needed for pH adjustment to 5.5 to 7.0.</item>
                  </list>
                  <paragraph>The amount of sodium in XERAVA lyophilized powder is negligible. Following reconstitution and dilution to a target concentration of 0.3 mg/mL in 0.9% Sodium Chloride Injection, USP, each XERAVA dose would contain 3.54 mg/mL of sodium <content styleCode="italics">[see <linkHtml href="#ID_e291adc8-5e0d-440a-b8e8-d142231c677e">Dosage and Administration (2.4)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="ID_86cb7053-9aa5-433d-a2cc-11b3e60e41cd">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xerava-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e7f59b14-7c3d-4a26-9275-579167ef924e">
               <id root="4c9328d1-3af9-4980-ac3e-580823ec5d09"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="ID_042c2ac4-2f69-48e3-841a-deef7dfa798f">
                     <id root="1adb9514-232a-4273-a1a9-a369593b779d"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Eravacycline is an antibacterial drug <content styleCode="italics">[see Microbiology (<linkHtml href="#ID_3bbe2352-ce01-4e81-a4c7-2a1483538e63">12.4</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_55019ac1-ba7f-4e3a-beb5-e948a5187132">
                     <id root="7402bcdc-62d2-46ba-ae71-c9a1f2198438"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>The AUC divided by the MIC of eravacycline has been shown to be the best predictor of activity. Based on the flat exposure-response relationship observed in clinical studies, eravacycline exposure achieved with the recommended dosage regimen appears to be on the plateau of the exposure-response curve. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>The effect of XERAVA on the QTc interval was evaluated in a Phase 1 randomized, placebo and positive controlled, double-blind, single-dose, crossover thorough QTc study in 60 healthy adult subjects. At the 1.5 mg/kg single dose (1.5 times the maximum approved recommended dose), XERAVA did not prolong the QTc interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d">
                     <id root="9c79d170-68ce-48ec-ba4e-9fe749ba2e44"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Following single-dose intravenous administration, eravacycline AUC and Cmax increase approximately dose-proportionally over doses from 1 mg/kg to 3 mg/kg (3 times the approved dose). </paragraph>
                        <paragraph>The mean exposure of eravacycline after single and multiple intravenous infusions (approximately 60 minutes) of 1 mg/kg administered to healthy adults every 12 hours is presented in Table 2.  </paragraph>
                        <paragraph>There is approximately 45% accumulation following intravenous dosing of 1 mg/kg every 12 hours.</paragraph>
                        <table width="75%">
                           <caption>Table 2: Mean (%CV) Plasma Exposure of Eravacycline After Single and Multiple Intravenous Dose in Healthy Adults</caption>
                           <col width="20%" align="center" valign="top"/>
                           <col width="40%" align="center" valign="top"/>
                           <col width="40%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th colspan="2" styleCode="Rrule">Exposure [Arithmetic Mean (%CV)]</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">C<sub>max</sub> (ng/mL)</th>
                                 <th styleCode="Rrule">AUC<sub>0-12</sub> (ng∙h/mL)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">Abbreviations: C<sub>max</sub> = maximum observed plasma concentration, CV = coefficient of variation; AUC<sub>0-12</sub> = area under the plasma concentration-time curve from time 0 to 12 hours.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">												Day 1 											</td>
                                 <td styleCode="Rrule">												2125 (15) 											</td>
                                 <td styleCode="Rrule">												4305 (14)<footnote>AUC of day 1 equals AUC<sub>0-12</sub> after the first dose of eravacycline.</footnote>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">												Day 10 											</td>
                                 <td styleCode="Rrule">												1825 (16) 											</td>
                                 <td styleCode="Rrule">												6309 (15)<footnote>AUC of day 10 equals steady state AUC<sub>0-12</sub>.</footnote>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Protein binding of eravacycline to human plasma proteins increases with increasing plasma concentrations, with 79% to 90% (bound) at plasma concentrations ranging from 100 to 10,000 ng/mL.  The volume of distribution at steady-state is approximately 321 L. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The mean elimination half-life is 20 hours.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>Eravacycline is metabolized primarily by CYP3A4- and FMO-mediated oxidation. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>Following a single intravenous dose of radiolabeled eravacycline 60 mg, approximately 34% of the dose is excreted in urine and 47% in feces as unchanged eravacycline (20% in urine and 17% in feces) and metabolites.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of eravacycline were observed based on age (18-86 years), sex, and race.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Patients with Renal Impairment </content>
                        </paragraph>
                        <paragraph>The geometric least square mean Cmax for eravacycline was increased by 8.8% for subjects with end stage renal disease (ESRD) versus healthy subjects with 90% CI -19.4, 45.2.  The geometric least square mean AUC0-inf for eravacycline was decreased by 4.0% for subjects with ESRD versus healthy subjects with 90% CI -14.0, 12.3 <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_9140c8ff-3b63-4110-8986-014f0fdd2042">8.7</linkHtml>)]</content>.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Patients with Hepatic Impairment </content>
                        </paragraph>
                        <paragraph>Eravacycline C<sub>max</sub> was 13.9%, 16.3%, and 19.7% higher in subjects with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), and severe (Child‑Pugh Class C) hepatic impairment versus healthy subjects, respectively.  Eravacycline AUC<sub>0-inf</sub> was 22.9%, 37.9%, and 110.3% higher in subjects with mild, moderate, and severe hepatic impairment versus healthy subjects, respectively <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_cacc3d19-8be5-4c5b-910c-ff8dcdc57a4c">2.2</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID_ddbc923f-d040-4fde-bdbe-dcbb70a4d3dd">8.6</linkHtml>)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies</content>
                        </paragraph>
                        <paragraph>Concomitant use of rifampin (strong CYP3A4/3A5 inducer) decreased eravacycline AUC by 35% and increased eravacycline clearance by 54% <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_1a770201-a6a0-4734-a79a-d62d44e98eec">2.3</linkHtml>) and Drug Interactions (<linkHtml href="#ID_1f272349-df5d-4cbb-90bc-4ac8fbaa272f">7.1</linkHtml>)]</content>. </paragraph>
                        <paragraph>Concomitant use of itraconazole (strong CYP3A inhibitor) increased eravacycline C<sub>max </sub>by 5% and AUC<sub>0-t</sub> by 32%, and decreased eravacycline clearance by 32%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies </content>
                        </paragraph>
                        <paragraph>Eravacycline is a substrate for the transporters P-gp, organic anion transporter peptide OATP1B1 and OATP1B3</paragraph>
                        <paragraph>Eravacycline is not a substrate for breast cancer resistance protein (BCRP), bile salt export pump (BSEP), organic ion transporter (OAT)1, OAT3, OCT1, OCT2, multidrug and toxin extrusion (protein) (MATE)1, or MATE2-K transporters.</paragraph>
                        <paragraph>Eravacycline is not an inhibitor of BCRP, BSEP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K transporters.</paragraph>
                        <paragraph>Eravacycline is not an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5. Eravacycline is not an inducer of CYP1A2, 2B6, or 3A4.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3bbe2352-ce01-4e81-a4c7-2a1483538e63">
                     <id root="e605aca0-2aed-492b-8efd-652b3c9a4b61"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>Eravacycline is a fluorocycline antibacterial within the tetracycline class of antibacterial drugs.  Eravacycline disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.</paragraph>
                        <paragraph>In general, eravacycline is bacteriostatic against gram-positive bacteria (e.g., <content styleCode="italics">Staphylococcus aureus</content> and <content styleCode="italics">Enterococcus faecalis</content>); however, <content styleCode="italics">in vitro</content> bactericidal activity has been demonstrated against certain strains of <content styleCode="italics">Escherichia coli</content> and <content styleCode="italics">Klebsiella pneumoniae</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance</content>
                        </paragraph>
                        <paragraph>Eravacycline resistance in some bacteria is associated with upregulated, non-specific intrinsic multidrug-resistant (MDR) efflux, and target-site modifications such as to the 16s rRNA or certain 30S ribosomal proteins (e.g., S10).</paragraph>
                        <paragraph>The C7 and C9 substitutions in eravacycline are not present in any naturally occurring or semisynthetic tetracyclines and the substitution pattern imparts microbiological activities including <content styleCode="italics">in vitro</content> activity against gram-positive and gram-negative strains expressing certain tetracycline-specific resistance mechanism(s) [i.e., efflux mediated by <content styleCode="italics">tet</content>(A), <content styleCode="italics">tet</content>(B), and <content styleCode="italics">tet</content>(K); ribosomal protection as encoded by <content styleCode="italics">tet</content>(M) and <content styleCode="italics">tet</content>(Q)].</paragraph>
                        <paragraph>Activity of eravacycline was demonstrated <content styleCode="italics">in vitro</content> against Enterobacteriaceae in the presence of certain beta-lactamases, including extended spectrum β-lactamases, and AmpC. However, some beta-lactamase-producing isolates may confer resistance to eravacycline via other resistance mechanisms. </paragraph>
                        <paragraph>The overall frequency of spontaneous mutants in the gram-positive organisms tested was in the range of 10<sup>-9</sup> to 10<sup>-10</sup> at 4 times the eravacycline Minimum Inhibitory Concentration (MIC).  Multistep selection of gram-negative strains resulted in a 16- to 32-times increase in eravacycline MIC for one isolate of <content styleCode="italics">Escherichia coli</content> and <content styleCode="italics">Klebsiella pneumoniae</content>, respectively.  The frequency of spontaneous mutations in <content styleCode="italics">K. pneumoniae</content> was 10<sup>-7</sup> to 10<sup>‑8</sup> at 4 times the eravacycline MIC.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Interaction with Other Antimicrobials</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> studies have not demonstrated antagonism between XERAVA and other commonly used antibacterial drugs for the indicated pathogens. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <paragraph>XERAVA has been shown to be active against most isolates of the following microorganisms, both <content styleCode="italics">in vitro</content> and in clinical infections <content styleCode="italics">[see Indications and Usage (<linkHtml href="#ID_12c989bd-6991-4078-badc-41db09126a49">1</linkHtml>)]</content>:</paragraph>
                        <paragraph>Aerobic bacteria</paragraph>
                        <paragraph>   Gram-positive bacteria</paragraph>
                        <paragraph>   <content styleCode="italics">Enterococcus faecalis<br/>
                           </content>   <content styleCode="italics">Enterococcus faecium<br/>
                           </content>   <content styleCode="italics">Staphylococcus aureus<br/>
                           </content>   <content styleCode="italics">Streptococcus anginosus</content> group</paragraph>
                        <paragraph>   Gram-negative bacteria<br/>   <content styleCode="italics">Citrobacter freundii<br/>
                           </content>   <content styleCode="italics">Enterobacter cloacae<br/>
                           </content>   <content styleCode="italics">Escherichia coli<br/>
                           </content>   <content styleCode="italics">Klebsiella oxytoca<br/>
                           </content>   <content styleCode="italics">Klebsiella pneumoniae</content>
                        </paragraph>
                        <paragraph>Anaerobic bacteria<br/>   Gram-positive bacteria<br/>   <content styleCode="italics">Clostridium perfringens</content>
                        </paragraph>
                        <paragraph>   Gram-negative bacteria<br/>   <content styleCode="italics">Bacteroides caccae<br/>
                           </content>   <content styleCode="italics">Bacteroides fragilis<br/>
                           </content>   <content styleCode="italics">Bacteroides ovatus<br/>
                           </content>   <content styleCode="italics">Bacteroides thetaiotaomicron<br/>
                           </content>   <content styleCode="italics">Bacteroides uniformis<br/>
                           </content>   <content styleCode="italics">Bacteroides vulgatus<br/>
                           </content>   <content styleCode="italics">Parabacteroides distasonis</content>
                        </paragraph>
                        <paragraph>The following <content styleCode="italics">in vitro</content> data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an <content styleCode="italics">in vitro</content> minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for eravacycline against isolates of similar genus or organism group. However, the efficacy of eravacycline in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.</paragraph>
                        <paragraph>Aerobic bacteria</paragraph>
                        <paragraph>   Gram-positive bacteria<br/>   <content styleCode="italics">Streptococcus salivarius</content> group</paragraph>
                        <paragraph>   Gram-negative bacteria<br/>   <content styleCode="italics">Citrobacter koseri<br/>
                           </content>   <content styleCode="italics">Enterobacter aerogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Test Methods</content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see https://www.fda.gov/STIC.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7d5c529f-68fb-4ec8-943a-30a374108a7a">
               <id root="1cde1b27-3249-48ed-a078-82adf68df915"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="ID_788fe52c-2e3e-41d8-b1e4-4101843e11dd">
                     <id root="a8c85ab4-9a83-49ae-a8f5-ef298b211259"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Carcinogenicity studies with eravacycline have not been conducted.  However, there has been evidence of oncogenic activity in rats in studies with the related antibacterial drugs, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). </paragraph>
                        <paragraph>Eravacycline was not genotoxic in a standard battery of assays, including an <content styleCode="italics">in vitro</content> mammalian cell mutation assay, an <content styleCode="italics">in vitro</content> clastogenicity assay, and an in vivo rat bone marrow micronucleus assay.</paragraph>
                        <paragraph>There are no human data on the effect of eravacycline on fertility.  Eravacycline did not affect mating or fertility in male rats following intravenous administration at a dose approximating a clinical dose of 0.65 mg/kg/day (approximately 1.5 times the clinical exposure, based on AUC determined in a separate study), however, eravacycline administration at higher doses was associated with adverse reactions on male fertility and spermatogenesis that were at least partially reversible after a 70-day recovery period (1 spermatogenic cycle).  Decreased sperm counts, abnormal sperm morphology, and reduced sperm motility were observed with testicular effects (impaired spermiation and sperm maturation).  There were no adverse reactions on mating or fertility in female rats administered intravenous eravacycline at a dose approximating a clinical dose of 3.2 mg/kg/day (approximately 18 times the clinical exposure based on AUC determined in a separate study in unmated females).</paragraph>
                        <paragraph>Decreased sperm counts and eravacycline‑related lesions noted in the testes and epididymides were seen in general toxicology studies in rats and were reversible.  These findings were anticipated effects for a tetracycline-class compound.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_decf1253-831f-4843-8338-9e02396bb3fb">
                     <id root="abe31d83-3da6-42d6-82c3-80b686d0725b"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>In repeated dose toxicity studies in rats, dogs and monkeys, lymphoid depletion/atrophy of lymph nodes, spleen and thymus, decreased erythrocytes, reticulocytes, leukocytes, and platelets (dog and monkey), in association with bone marrow hypocellularity, and adverse gastrointestinal effects (dog and monkey) were observed with eravacycline. These findings were reversible or partially reversible during recovery periods of 3 to 7 weeks.</paragraph>
                        <paragraph>Bone discoloration, which was not fully reversible over recovery periods of up to 7 weeks, was observed in rats and monkeys after 13 weeks of dosing and in the juvenile rat study after dosing over post-natal days 21-70.</paragraph>
                        <paragraph>Intravenous administration of eravacycline has been associated with a histamine response in rat and dog studies.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8c994f8e-dc98-4c97-b4ef-0fec668cf69b">
               <id root="6de7c176-421a-4ea2-a27e-d7cbed1eb2fa"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="ID_be43b4ac-847d-48e6-8654-73cde4f6d12e">
                     <id root="fa0e8ddc-2f9e-4355-a092-8c07dac867f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Complicated Intra-abdominal Infections in Adults</title>
                     <text>
                        <paragraph>A total of 1,041 adults hospitalized with cIAI were enrolled in two Phase 3, randomized, double-blind, active-controlled, multinational, multicenter trials (Trial 1, NCT01844856, and Trial 2, NCT02784704). These studies compared XERAVA (1 mg/kg intravenous every 12 hours) with either ertapenem (1 g every 24 hours) or meropenem (1 g every 8 hours) as the active comparator for 4 to 14 days of therapy. Complicated intra-abdominal infections included appendicitis, cholecystitis, diverticulitis, gastric/duodenal perforation, intra-abdominal abscess, perforation of intestine, and peritonitis.</paragraph>
                        <paragraph>The microbiologic intent-to-treat (micro-ITT) population, which included all patients who had at least one baseline intra-abdominal pathogen, consisted of 846 patients in the two trials. Populations in Trial 1 and Trial 2 were similar. The median age was 56 years and 56% were male. The majority of patients (95%) were from Europe; 5% were from the United States. The most common primary cIAI diagnosis was intra-abdominal abscess(es), occurring in 60% of patients. Bacteremia at baseline was present in 8% of patients.</paragraph>
                        <paragraph>Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the index infection at the Test of Cure (TOC) visit which occurred 25 to 31 days after randomization. Selected clinical responses were reviewed by a Surgical Adjudication Committee. Table 3 presents the clinical cure rates in the micro-ITT population. Clinical cure rates at the TOC visit for selected pathogens are presented in Table 4.</paragraph>
                        <table width="85%">
                           <caption>Table 3: Clinical Cure Rates at TOC in the Phase 3 cIAI Trials, Micro-ITT Population</caption>
                           <col width="35%" align="left" valign="top"/>
                           <col width="15%" align="center" valign="top"/>
                           <col width="15%" align="center" valign="top"/>
                           <col width="15%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th colspan="2" styleCode="Rrule Botrule">												Trial 1 											</th>
                                 <th colspan="2" styleCode="Botrule Rrule">												Trial 2 											</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">												XERAVA<footnote ID="Tb3fta">XERAVA dose equals 1 mg/kg every 12 hours IV.</footnote>
                                    <br/>N=220<br/>n (%) 											</th>
                                 <th styleCode="Rrule">												Ertapenem<footnote>Ertapenem dose equals1 g every 24 hours IV</footnote>
                                    <br/>N=226<br/>n (%) 											</th>
                                 <th styleCode="Rrule">												XERAVA<footnoteRef IDREF="Tb3fta"/>
                                    <br/>N=195<br/>n (%)</th>
                                 <th styleCode="Rrule">												Meropenem<footnote>Meropenem dose equals 1 g every 8 hours IV.</footnote>
                                    <br/>N=205<br/>n (%)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">Abbreviations: CI = confidence interval; IV = intravenous; micro-ITT = all randomized subjects who had baseline bacterial pathogens that caused cIAI and against at least one of which the investigational drug has <content styleCode="italics">in vitro</content> antibacterial activity; N = number of subjects in the micro-ITT population; n = number within a specific category with a clinical cure based on the Surgical Adjudication Committee assessment (if available); TOC = Test of Cure.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Clinical cure</content>
                                 </td>
                                 <td styleCode="Rrule">												191 (86.8) 											</td>
                                 <td styleCode="Rrule">												198 (87.6) 											</td>
                                 <td styleCode="Rrule">												177 (90.8) 											</td>
                                 <td styleCode="Rrule">												187 (91.2) 											</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Difference (95% CI)</content>
                                    <footnote>Treatment Difference = Difference in clinical cure rates (eravacycline minus ertapenem or meropenem). Confidence intervals are calculated using the unadjusted Miettinen-Nurminen method</footnote>
                                 </td>
                                 <td colspan="2" styleCode="Rrule">-0.80 (-7.1, 5.5)</td>
                                 <td colspan="2" styleCode="Rrule">-0.5 (-6.3, 5.3) 											</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="85%">
                           <caption>Table 4: Clinical Cure Rates at TOC by Selected Baseline Pathogens in Pooled Phase 3 cIAI Trials, Micro-ITT Population</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th valign="bottom" styleCode="Lrule Rrule">												Pathogen 											</th>
                                 <th styleCode="Rrule">												XERAVA<footnote>XERAVA dose equals 1 mg/kg every 12 hours IV.</footnote>
                                    <br/>N=415<br/>n/N1 (%) 											</th>
                                 <th styleCode="Rrule">												Comparators<footnote>Comparators include Ertapenem 1 g every 24 hours IV and Meropenem 1 g every 8 hours IV.</footnote>
                                    <br/>N=431<br/>n/N1 (%) 											</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">Abbreviations: IV = intravenous; N = Number of subjects in the micro-ITT Population; N1 = Number of subjects with a specific pathogen; n = Number of subjects with a clinical cure at the TOC visit. Percentages are calculated as 100 × (n/N1); TOC = Test of Cure</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">												Enterobacteriaceae 											</td>
                                 <td styleCode="Rrule">												271/314 (86.3) 											</td>
                                 <td styleCode="Rrule">												289/325 (88.9) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Citrobacter freundii</content>
                                 </td>
                                 <td styleCode="Rrule">												19/22 (86.4) 											</td>
                                 <td styleCode="Rrule">												8/10 (80.0) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Enterobacter cloacae</content> complex 											</td>
                                 <td styleCode="Rrule">												17/21 (81.0) 											</td>
                                 <td styleCode="Rrule">												23/24 (95.8) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Escherichia coli</content>
                                 </td>
                                 <td styleCode="Rrule">												220/253 (87.0) 											</td>
                                 <td styleCode="Rrule">												237/266 (89.1) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Klebsiella oxytoca</content>
                                 </td>
                                 <td styleCode="Rrule">												14/15 (93.3) 											</td>
                                 <td styleCode="Rrule">												16/19 (84.2) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Klebsiella pneumoniae</content>
                                 </td>
                                 <td styleCode="Rrule">												37/39 (94.9) 											</td>
                                 <td styleCode="Rrule">												42/50 (84.0) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Enterococcus faecalis</content>
                                 </td>
                                 <td styleCode="Rrule">												45/54 (83.3) 											</td>
                                 <td styleCode="Rrule">												47/54 (87.0) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Enterococcus faecium</content>
                                 </td>
                                 <td styleCode="Rrule">												38/45 (84.4) 											</td>
                                 <td styleCode="Rrule">												48/53 (90.6) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Staphylococcus aureus</content>
                                 </td>
                                 <td styleCode="Rrule">												24/24 (100.0) 											</td>
                                 <td styleCode="Rrule">												12/14 (85.7) 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Streptococcus anginosus</content> group<footnote>Includes Streptococcus anginosus, Streptococcus constellatus, and Streptococcus intermedius</footnote>
                                 </td>
                                 <td styleCode="Rrule">												79/92 (85.9) 											</td>
                                 <td styleCode="Rrule">												50/59 (84.7) 											</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">												Anaerobes<footnote>Includes Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Parabacteroides distasonis.</footnote>
                                 </td>
                                 <td styleCode="Rrule">												186/215 (86.5) 											</td>
                                 <td styleCode="Rrule">												194/214 (90.7) 											</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_04ce8778-fbe2-42d7-a27b-d761c55cbad6">
                     <id root="9bba2307-a3d1-48a9-abb1-aee31e88e53f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Complicated Urinary Tract Infections (cUTI) in Adults </title>
                     <text>
                        <paragraph>Two randomized, double-blind, active-controlled, clinical trials (Trial 4, NCT01978938, and Trial 5, NCT03032510) evaluated the efficacy and safety of once-daily intravenous eravacycline for the treatment of patients with complicated urinary tract infections (cUTI). Trial 4 included an optional switch from IV to oral therapy with eravacycline. The trials did not demonstrate the efficacy of XERAVA for the combined endpoints of clinical cure and microbiological success in the microbiological intent-to-treat (micro-ITT) population at the test-of-cure visit <content styleCode="italics">[see Indications and Usage (<linkHtml href="#ID_12c989bd-6991-4078-badc-41db09126a49">1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_cc9a8e88-7e9a-419c-973e-45450c269377">
               <id root="cb5761b9-aa24-4fe2-bace-dac4dd74c100"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="ID_7af38901-8879-4b54-9ec7-b56b31be08d9">
                     <id root="bbf1e759-b3c8-497e-a785-37d46e2db48d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied </title>
                     <text>
                        <paragraph>XERAVA (eravacycline) for injection is a yellow to orange, sterile, preservative-free powder for reconstitution in single-dose 10-mL clear glass vials with a rubber stopper and an aluminum overseal. XERAVA is supplied in the following configurations:</paragraph>
                        <list listType="unordered">
                           <item>XERAVA 50 mg vial contains 50 mg of eravacycline (equivalent to 63.5 mg of eravacycline dihydrochloride). Each vial is packaged in a single-dose vial carton (NDC 71773-050-05) and supplied in a 12-vial carton containing 12 single-dose vial cartons— NDC 71773-050-12.</item>
                           <item>XERAVA 100 mg vial contains 100 mg of eravacycline (equivalent to 127 mg of eravacycline dihydrochloride). Each vial is packaged in a single-dose vial carton (NDC 71773-100-05) and supplied in shrink wrap packaging, containing 12 single-dose vial cartons— NDC 71773-100-12.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c5d26626-f7af-4d19-bf6d-695dc221bb94">
                     <id root="417bea30-1bef-4d1e-808a-2659b6604d00"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling </title>
                     <text>
                        <paragraph>Prior to reconstitution, XERAVA should be stored at 2°C to 8°C (36°F to 46°F) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_e291adc8-5e0d-440a-b8e8-d142231c677e">2.4</linkHtml>)].</content> Keep vial in carton until use.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_45266de0-f533-48d9-b46d-f2726d777958">
               <id root="416c433f-a650-4993-ae21-8e1384601597"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Serious Allergic Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. Ask patient about any previous hypersensitivity reactions to antibacterial drugs including tetracycline or other allergens <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_9e37a7d7-ea50-46ca-934c-1605bf33c856">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Tooth Discoloration and Inhibition of Bone Growth</content>
                  </paragraph>
                  <paragraph>Advise patients that XERAVA, like other tetracycline-class drugs, may cause permanent tooth discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy. Advise patients that they should tell their healthcare provider right away if they become pregnant <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_a0412d53-1485-4084-9e90-8b7919a79779">5.2</linkHtml>, <linkHtml href="#ID_b8b6bbaa-7734-4531-b453-59aee592b3f4">5.3</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID_eaa6d5fd-17eb-4fcb-9811-853d5ab7f44f">8.1</linkHtml>, <linkHtml href="#ID_ee4ac1ba-ab86-44cf-a8f1-bbb402e0dfee">8.4</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with XERAVA and for 4 days after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_2d8b6b6a-fa0d-4906-bd83-18d4611d6864">8.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Diarrhea</content>
                  </paragraph>
                  <paragraph>Diarrhea is a common problem caused by antibacterial drugs, including XERAVA, which usually ends when the antibacterial drug is discontinued. Sometimes after starting treatment with antibacterial drug, patients can develop watery and bloody stools (with or without stomach cramps and fever) which may be a sign of a more serious intestinal infection, even as late as 2 or more months after having taken the last dose of the antibacterial drug. If this occurs, instruct patients to contact their healthcare provider as soon as possible <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_2fb939d7-7b08-4c58-926c-0b274feebc69">5.4</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Tetracycline Class Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients that XERAVA is similar to tetracycline-class antibacterial drugs and may have similar adverse reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_eccd5b86-837b-4e59-897f-15ff76a9087f">5.5</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Overgrowth of Non-susceptible Microorganisms</content>
                  </paragraph>
                  <paragraph>Inform patients that antibacterial drugs including XERAVA may promote the overgrowth of non-susceptible microorganisms, including fungi <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_2d7ede7e-3125-4540-8f1c-bb8af583f988">5.6</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Antibacterial Resistance</content>
                  </paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs including XERAVA should only be used to treat bacterial infections. They do not treat viral infections (for example, the common cold). When XERAVA is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by XERAVA or other antibacterial drugs in the future.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="ID_1dfb23ec-0e50-4320-984f-3823d05bcdc1">
               <id root="042a0e3f-2a46-431f-957a-379f56d8f926"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed by:<br/>
                     <br/>Tetraphase Pharmaceuticals, Inc.<br/>Waltham, MA 02451</paragraph>
                  <paragraph/>
                  <paragraph>XERAVA is a registered trademark of Tetraphase Pharmaceuticals, Inc.<br/>
                     <br/>             ©2025 Tetraphase Pharmaceuticals, Inc. All rights reserved.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="ID_f569b0b6-17a2-4502-97fd-d5d32e4cae1c">
               <id root="6d9ac190-7020-4fd6-817a-8075cd8cb282"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 50 mg Vial Carton</title>
               <text>
                  <paragraph>NDC 71773-050-05<br/>Rx only</paragraph>
                  <paragraph>XERAVA™<br/>(eravacycline) for injection</paragraph>
                  <paragraph>50 mg per vial</paragraph>
                  <paragraph>MUST BE<br/>RECONSTITUTED<br/>THEN DILUTED.</paragraph>
                  <paragraph>For Intravenous Infusion Only.<br/>See Prescribing Information<br/>for complete directions for use.</paragraph>
                  <paragraph>1 Single-Dose Vial<br/>Not labeled for individual sale</paragraph>
                  <paragraph>TETRAPHASE<br/>PHARMACEUTICALS</paragraph>
                  <renderMultiMedia referencedObject="img_cddccac9-8e4e-a511-e053-2a95a90aa005"/>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="img_cddccac9-8e4e-a511-e053-2a95a90aa005">
                     <text>PRINCIPAL DISPLAY PANEL - 50 mg Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xerava-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_90f57399-fabd-456e-8a35-d0277afe01cb">
               <id root="bc764f62-a899-4b21-9c47-cd179045b4bd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg Vial Carton</title>
               <text>
                  <paragraph>NDC 71773-100-05<br/>Rx only</paragraph>
                  <paragraph>XERAVA™<br/>(eravacycline) for injection</paragraph>
                  <paragraph>100 mg per vial</paragraph>
                  <paragraph>MUST BE<br/>RECONSTITUTED<br/>THEN DILUTED.</paragraph>
                  <paragraph>For Intravenous Infusion Only.<br/>See Prescribing Information for<br/> complete directions for use.</paragraph>
                  <paragraph>1 Single-Dose Vial<br/>Not labeled for Individual sale</paragraph>
                  <paragraph>TETRAPHASE<br/>PHARMACEUTICALS</paragraph>
                  <renderMultiMedia referencedObject="img_cddb5244-f3ef-5add-e053-2995a90a63c5"/>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="img_cddb5244-f3ef-5add-e053-2995a90a63c5">
                     <text>PRINCIPAL DISPLAY PANEL - 100 mg Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xerava-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>